Rozhkov Andrey N, Shchekochikhin Dmitry Yu, Ashikhmin Yaroslav I, Mitina Yulia O, Evgrafova Veronika V, Zhelankin Andrey V, Gognieva Daria G, Akselrod Anna S, Kopylov Philippe Yu
World-Class Research Center "Digital Biodesign and Personalized Healthcare", I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Department of Cardiology, Functional and Ultrasound Diagnostics, N.V. Sklifosovsky Institute of Clinical Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Noncoding RNA. 2022 Jun 29;8(4):47. doi: 10.3390/ncrna8040047.
Non-coding RNAs reflect many biological processes in the human body, including athero-sclerosis. In a cardiology outpatient department cohort (N = 83), we aimed to compare the levels of circulating microRNAs in groups with vulnerable plaques (N = 22), stable plaques (N = 23) and plaque-free (N = 17) depending on coronary computed tomography angiography and to evaluate associations of microRNA levels with calculated cardiovascular risks (CVR), based on the SCORE2 (+OP), ACC/AHA, ATP-III and MESA scales. Coronary computed tomography was performed on a 640-slice computed tomography scanner. Relative plasma levels of microRNA were assessed via a real-time polymerase chain reaction. We found significant differences in miR-143-3p levels (p = 0.0046 in plaque-free vs. vulnerable plaque groups) and miR-181b-5p (p = 0.0179 in stable vs. vulnerable plaques groups). Analysis of microRNA associations with CVR did not show significant differences for SCORE2 (+OP) and ATPIII scales. MiR-126-5p and miR-150-5p levels were significantly higher (p < 0.05) in patients with ACC/AHA risk >10% and miR-145-5p had linear relationships with ACC/AHA score (adjusted p = 0.0164). The relative plasma level of miR-195 was higher (p < 0.05) in patients with MESA risk > 7.5% and higher (p < 0.05) in patients with zero coronary calcium index (p = 0.036). A linear relationship with coronary calcium was observed for miR-126-3p (adjusted p = 0.0484). A positive correlation with high coronary calcium levels (> 100 Agatson units) was found for miR-181-5p (p = 0.036). Analyzing the biological pathways of these microRNAs, we suggest that miR-143-3p and miR-181-5p can be potential markers of the atherosclerosis process. Other miRNAs (miR-126-3p, 126-5p, 145-5p, 150-5p, 195-5p) can be considered as potential cardiovascular risk modifiers, but it is necessary to validate our results in a large prospective trial.
非编码RNA反映了人体中的许多生物学过程,包括动脉粥样硬化。在一个心脏病门诊队列(N = 83)中,我们旨在根据冠状动脉计算机断层扫描血管造影术,比较有易损斑块组(N = 22)、稳定斑块组(N = 23)和无斑块组(N = 17)中循环微RNA的水平,并基于SCORE2(+OP)、美国心脏病学会/美国心脏协会(ACC/AHA)、成人治疗小组第三次报告(ATP-III)和多族裔动脉粥样硬化研究(MESA)量表,评估微RNA水平与计算出的心血管风险(CVR)之间的关联。冠状动脉计算机断层扫描在一台640层计算机断层扫描仪上进行。通过实时聚合酶链反应评估微RNA的相对血浆水平。我们发现,miR-143-3p水平存在显著差异(无斑块组与易损斑块组相比,p = 0.0046),miR-181b-5p也有显著差异(稳定斑块组与易损斑块组相比,p = 0.0179)。对微RNA与CVR关联的分析显示,SCORE2(+OP)和ATPIII量表没有显著差异。ACC/AHA风险>10%的患者中,miR-126-5p和miR-150-5p水平显著更高(p < 0.05),且miR-145-5p与ACC/AHA评分呈线性关系(校正p = 0.0164)。MESA风险>7.5%的患者中,miR-195的相对血浆水平更高(p < 0.05),冠状动脉钙指数为零的患者中该水平也更高(p = 0.036)。观察到miR-126-3p与冠状动脉钙化呈线性关系(校正p = 0.0484)。发现miR-181-5p与高冠状动脉钙化水平(>100阿加特森单位)呈正相关(p = 0.036)。分析这些微RNA的生物学途径,我们认为miR-143-3p和miR-181-5p可能是动脉粥样硬化过程的潜在标志物。其他微RNA(miR-126-3p、126-5p、145-5p、150-5p、195-5p)可被视为潜在的心血管风险调节因子,但有必要在一项大型前瞻性试验中验证我们的结果。